{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:01:27Z","timestamp":1790820087766,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"DAIICHI SANKYO COMPANY, LIMITED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["956146"],"award-info":[{"award-number":["956146"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.023","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:21:08Z","timestamp":1751563268000},"page":"3251-3262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-473X","authenticated-orcid":false,"given":"Angela Elma","family":"Edwina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-1891","authenticated-orcid":false,"given":"Lorenz","family":"Van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-7181","authenticated-orcid":false,"given":"Kathrin","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-1698","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8698-2858","authenticated-orcid":false,"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-8918","authenticated-orcid":false,"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0265-9154","authenticated-orcid":false,"given":"Jos","family":"Tournoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.023_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/europace\/eus333","article-title":"Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients","volume":"15","author":"Wilke","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2025.06.023_bib2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ageing\/afaa265","article-title":"Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study","volume":"50","author":"Wilkinson","year":"2021","journal-title":"Age Ageing"},{"key":"10.1016\/j.jtha.2025.06.023_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.06.023_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.06.023_bib5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.023_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ahj.2015.11.004","volume":"172","author":"Eisen","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2025.06.023_bib7","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.023_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","article-title":"Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism","volume":"41","author":"Witt","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.023_bib9","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.023_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1532-5415.2007.01156.x","article-title":"Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept","volume":"55","author":"Inouye","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jtha.2025.06.023_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.jtha.2025.06.023_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11239-020-02326-x","article-title":"Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing","volume":"52","author":"Kampouraki","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.023_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/bcp.15049","article-title":"Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians","volume":"88","author":"Hias","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.023_bib14","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.023_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.023_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.023_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.06.023_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12680","article-title":"The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma","volume":"6","author":"Siriez","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.023_bib19","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jtha.2025.06.023_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ageing\/afl041","article-title":"Validity and reliability of the Edmonton Frail Scale","volume":"35","author":"Rolfson","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.jtha.2025.06.023_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2025.06.023_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpba.2017.10.011","article-title":"Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy","volume":"148","author":"Foerster","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jtha.2025.06.023_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10928-011-9201-9","article-title":"Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models","volume":"38","author":"Xu","year":"2011","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtha.2025.06.023_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtha.2025.06.023_bib25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.023_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Martin Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.023_bib27","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I","volume":"21","author":"Passing","year":"1983","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.jtha.2025.06.023_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40262-016-0378-3","article-title":"Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial","volume":"55","author":"Krekels","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.06.023_bib29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jcph.541","article-title":"Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study","volume":"55","author":"J\u00f6nsson","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.023_bib30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2025.06.023_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modeling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.023_bib32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jcph.306","article-title":"Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment","volume":"54","author":"Song","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.023_bib33","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00228-014-1736-4","article-title":"Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation","volume":"70","author":"Yin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.023_bib34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jtha.2025.06.023_bib35","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s11255-017-1682-z","article-title":"Estimating renal function in old people: an in-depth review","volume":"49","author":"Raman","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jtha.2025.06.023_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40266-015-0318-1","article-title":"Age-related changes in hepatic function: an update on implications for drug therapy","volume":"32","author":"Tan","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jtha.2025.06.023_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120349","article-title":"Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model","volume":"597","author":"Kato","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jtha.2025.06.023_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1532-5415.1965.tb02665.x","article-title":"The effect of increasing age on the distribution of peripheral blood flow in man","volume":"13","author":"Bender","year":"1965","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jtha.2025.06.023_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125016","article-title":"Tracking the journey: gastrointestinal transit and intraluminal pH dynamics in aging populations using wireless motility capsule","volume":"669","author":"Edwina","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jtha.2025.06.023_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109118","article-title":"Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance \u226595 ml\/min?\u2014a population pharmacokinetic analysis","volume":"242","author":"Clapham","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.023_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1103","article-title":"Risk factors associated with mortality and neurologic disability after intracerebral hemorrhage in a racially and ethnically diverse cohort","volume":"5","author":"Woo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.06.023_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.023_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2021.02.034","article-title":"Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: impact on plasma drug levels","volume":"201","author":"Comans","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.023_bib45","series-title":"2022. Lecture Notes in Bioengineering","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-031-29067-1_24","article-title":"Difficult intravenous access in older adults with cancer: can vein-locating technology be key for vessel health?","author":"Santos-Costa","year":"2023"},{"key":"10.1016\/j.jtha.2025.06.023_bib46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jtha.2025.06.023_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132484","article-title":"MAS Study group. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events","volume":"416","author":"Palareti","year":"2024","journal-title":"Int J Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500412X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500412X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:23:41Z","timestamp":1790817821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500412X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S153878362500412X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.023","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}